Drugs / IMP-288
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01273402 | Feb 2011 → Feb 2013 | colorectal cancer | Gilead Sciences | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00860860 | Jul 2009 → Oct 2011 | colorectal neoplasm | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02587247 | Mar 2016 → Jan 2017 | colorectal cancer | Nantes University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMP288 | “the [68Ga]Ga-labelled HSG peptide, IMP288, in patients with metastatic colorectal carcinoma (CRC).” PMID 32820369 ↗ Aug 20204“111In/90Y-labeled hapten-peptide (IMP-288)” NCT01273402 ↗ “Lu-177-labeled di-HSG-DOTA peptide IMP-288” NCT00860860 ↗ |
| Modality | Peptide | “Lu-177-labeled di-HSG-DOTA peptide IMP-288” NCT00860860 ↗ |
| Route | Intravenous | “patients received intravenously 120 nmol of TF2 followed 30 h later by 150 MBq of [68Ga]Ga-labelled IMP288, both I.V.” PMID 32820369 ↗ Aug 2020 |